MAM
UBX

Martingale Asset Management’s Unity Biotechnology UBX Stock Holding History

Martingale Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,560
Closed -$124K – 1041
2020
Q3 		$124K Sell
3,560
-15,412
-81% -$976K ﹤0.01% 1002
2020
Q2 		$1.65M Buy
+18,972
New +$1.41M 0.02% 590

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Martingale Asset Management's UBX Position: Q4 2020 in Review

Martingale Asset Management sold out of Unity Biotechnology (UBX) in Q4 2020, closing a stake of 3,560 shares — an estimated $124K sold.

Martingale Asset Management first reported a position in UBX in Q2 2020 and held it in 2 quarters. The position peaked at $1.65M in Q2 2020. 85 funds tracked by Wall St. Rank hold UBX as of Q4 2020.

  • Martingale Asset Management reported no remaining Unity Biotechnology position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 3,560 Unity Biotechnology shares in Q4 2020, an estimated $124K.
  • Martingale Asset Management first reported a position in Unity Biotechnology in Q2 2020 and held it in 2 quarters.
  • Martingale Asset Management's Unity Biotechnology position peaked at $1.65M in Q2 2020.
  • 85 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.